{"meshTags":["Drug Tolerance","Mutation","Humans","Protein Kinase Inhibitors","Melanoma"],"meshMinor":["Drug Tolerance","Mutation","Humans","Protein Kinase Inhibitors","Melanoma"],"genes":["HIV1 protease","MITF","MAPK","NRAS","BRAF","NRAS","MEK"],"organisms":["12721","11676","6755"],"publicationTypes":["Comment","Journal Article"],"abstract":"The HIV1 protease inhibitor nelfinavir is being investigated as a cancer therapeutic. In this issue of Cancer Cell, Smith etÂ al. (2016) report that nelfinavir suppresses MITF expression induced by MAPK pathway inhibition in melanoma cells and sensitizes melanoma cells with NRAS or BRAF plus NRAS mutations to MEK inhibitors. ","title":"HIV Drug to Aid Melanoma Therapies?","pubmedId":"26977874"}